The revolutionary new drug avoids the appearance of metastases in 80% and local recurrences of human breast cancer in 75% of cases.

In the new JEM study, teams used a computer-based screening approach to identify a drug, named C26, that activates NR2F1.

The most aggressive triple negative breast cancer affects 1,000 patients per year in Belgium, while the figure worldwide is 225,000.

A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state.